MarketPeel
Insider Trading Intelligence
JO

Jose Manuel Otero

LXEO
CHIEF OPERATING OFFICER · LEXEO THERAPEUTICS, INC. · CIK 0002024096
FILING MIX · LIFETIME56%/44%
BUYS
10
SELLS
8
TOTAL VALUE
$123.0K
COMPANIES
1
ACTIVE SINCE
Jun 2024
HOLDINGS NOW
137,482
AVG SELL PX
$6.00
TRADE KIND
SHOWING 18 / 18
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
6 backtested trades · 8 horizons · 13 pending
Forward-return performance of every backtestable P/S trade by Jose Manuel Otero, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d6+66.67%-0.41%+1.15%-1.55%-5.16%
14d6+50.00%+1.57%+1.24%+0.33%-0.17%
30d6+50.00%+2.35%+0.39%+1.97%+2.39%
60d6+16.67%+29.48%+3.16%+26.32%-0.03%
90d6+66.67%+13.60%+4.49%+9.10%-25.90%
180d6(1 pending)+60.00%-8.00%+7.02%-15.02%-34.37%
1y6(6 pending)
2y6(6 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
LXEO · 137,482 shares · as of Jul 1, 2026
065,000130,000195,000260,00020252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2024
2024
2024
2025
2025
2025
2025
2026
2026
2026
FLOW · 10 buys / 8 sellsCOVERAGE · 10 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
LXEO
LEXEO THERAPEUTICS, INC.
SALE
Chief Operating Officer
4,666$4.48$20.9K137,482Jul 1, 2026Jul 1, 2026View →
LXEO
LEXEO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
12,060142,148Jun 29, 2026Jul 1, 2026View →
LXEO
LEXEO THERAPEUTICS, INC.
SALE
Chief Operating Officer
1,302$5.07$6.6K130,088May 18, 2026May 20, 2026View →
LXEO
LEXEO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,930$2.64$15.7K131,390Mar 13, 2026Mar 17, 2026View →
LXEO
LEXEO THERAPEUTICS, INC.
SALE
Chief Operating Officer
3,016$6.40$19.3K125,460Feb 18, 2026Feb 20, 2026View →
LXEO
LEXEO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
260,000260,000Feb 4, 2026Feb 6, 2026View →
LXEO
LEXEO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
65,000128,476Feb 4, 2026Feb 6, 2026View →
LXEO
LEXEO THERAPEUTICS, INC.
SALE
Chief Operating Officer
721$9.27$6.7K63,476Nov 18, 2025Feb 20, 2026View →
LXEO
LEXEO THERAPEUTICS, INC.
SALE
Chief Technical Officer
2,091$8.94$18.7K64,221Oct 17, 2025Oct 17, 2025View →
LXEO
LEXEO THERAPEUTICS, INC.
SALE
Chief Technical Officer
24$9.56$22964,197Oct 17, 2025Oct 17, 2025View →
LXEO
LEXEO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,94066,312Oct 15, 2025Oct 17, 2025View →
LXEO
LEXEO THERAPEUTICS, INC.
SALE
Chief Technical Officer
2,848$4.67$13.3K60,372Aug 18, 2025Aug 20, 2025View →
LXEO
LEXEO THERAPEUTICS, INC.
SALE
Chief Technical Officer
721$9.27$6.7K63,476Aug 18, 2025Nov 20, 2025View →
LXEO
LEXEO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,720$2.61$14.9K63,220Mar 14, 2025Apr 9, 2025View →
LXEO
LEXEO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
26,25057,500Jan 7, 2025Jan 10, 2025View →
LXEO
LEXEO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
52,50052,500Jan 7, 2025Jan 10, 2025View →
LXEO
LEXEO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
187,500187,500Jun 12, 2024Jun 14, 2024View →
LXEO
LEXEO THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
31,25031,250Jun 12, 2024Jun 14, 2024View →
Other insiders · LXEO
Loading peer insiders…
About this filer
CIK 0002024096
ROLE
Chief Operating Officer
PRIMARY
LXEO
COMPANIES
1
ACTIVE SINCE
Jun 2024
MARKETPEEL · /INSIDER/0002024096DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback